Production (Stage)
Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$1.09
-$0.15-12.10%
OTC PK
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 215.77M | 232.43M | 269.97M | 269.97M | 247.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 215.77M | 232.43M | 269.97M | 269.97M | 247.31M |
| Cost of Revenue | 80.26M | 85.88M | 97.15M | 97.15M | 85.88M |
| Gross Profit | 135.51M | 146.55M | 172.82M | 172.82M | 161.42M |
| SG&A Expenses | 88.53M | 104.04M | 116.13M | 116.13M | 111.02M |
| Depreciation & Amortization | -- | -3.91M | -- | -- | -- |
| Other Operating Expenses | -56.90K | -616.40K | -371.90K | -371.90K | -105.90K |
| Total Operating Expenses | 168.73M | 185.40M | 212.90M | 212.90M | 196.80M |
| Operating Income | 47.04M | 47.03M | 57.07M | 57.07M | 50.51M |
| Income Before Tax | 34.34M | 29.85M | 48.91M | 48.91M | 34.00M |
| Income Tax Expenses | 9.91M | 8.56M | 12.25M | 12.25M | 8.54M |
| Earnings from Continuing Operations | 24.42M | 21.29M | 36.66M | 36.66M | 25.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -3.53M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.42M | 21.29M | 36.66M | 36.66M | 21.92M |
| EBIT | 47.04M | 47.03M | 57.07M | 57.07M | 50.51M |
| EBITDA | 51.79M | 53.07M | 60.54M | 60.54M | 55.81M |
| EPS Basic | 0.03 | 0.02 | 0.04 | 0.04 | 0.02 |
| Normalized Basic EPS | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 |
| EPS Diluted | 0.03 | 0.02 | 0.04 | 0.04 | 0.02 |
| Normalized Diluted EPS | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 |
| Average Basic Shares Outstanding | 977.88M | 986.44M | 942.75M | 942.75M | 930.27M |
| Average Diluted Shares Outstanding | 977.88M | 986.44M | 942.75M | 942.75M | 930.27M |
| Dividend Per Share | -- | 0.03 | -- | -- | 0.01 |
| Payout Ratio | 39.18% | 42.86% | 32.96% | 32.96% | 51.55% |